LEIDEN, THE NETHERLANDS--(Marketwire - March 25, 2008) - Dutch biotechnology company Crucell N.V. today announced a non-exclusive STAR® research license agreement with biopharmaceutical company Medarex for the production of monoclonal antibodies. Financial details of the agreement were not disclosed.
